MAGEA3 Overexpression serves as an inclusion eligibility criterion in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials that contain MAGEA3 Overexpression as an inclusion criterion, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
Trials with MAGEA3 Overexpression in the inclusion eligibility criteria most commonly target head and neck squamous cell carcinoma and non-small cell lung carcinoma .
Significance of MAGEA3 Overexpression in Diseases
Head And Neck Squamous Cell Carcinoma +
MAGEA3 Overexpression is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MAGEA3 Overexpression and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) .
Non-Small Cell Lung Carcinoma +
MAGEA3 Overexpression is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAGEA3 Overexpression and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.